Vitamin d and Tabrecta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vitamin d (ergocalciferol) and Tabrecta (capmatinib hydrochloride). Common drug interactions include fatigue among females and amylase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Vitamin d and Tabrecta. It is created by eHealthMe based on reports of 37 people who take the same drugs from the FDA, and is updated regularly.

What is Vitamin d?

Vitamin d has active ingredients of ergocalciferol. It is often used in low vitamin d. eHealthMe is studying from 294,095 Vitamin d users. Check the latest studies of Vitamin d.

What is Tabrecta?

Tabrecta has active ingredients of capmatinib hydrochloride. eHealthMe is studying from 2,095 Tabrecta users. Check the latest studies of Tabrecta.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

37 people who take Vitamin d and Tabrecta together, and have interactions are studied.

Vitamin d and Tabrecta drug interactions.

What are the common drug interactions of Vitamin D and Tabrecta, by gender? *:

female:

Fatigue (feeling of tiredness)
Peripheral swelling
Asthenia (weakness)
Neoplasm malignant (cancer tumour)
Swelling
Decreased appetite
Dehydration (dryness resulting from the removal of water)
Feeding disorder (when children refuse to eat certain food groups)
Muscle spasms (muscle contraction)
Nausea (feeling of having an urge to vomit)

male:

Amylase increased
Asthenia (weakness)
Chylothorax (collection of lymph fluid around the lung)
Conjunctivitis (pink eye)
Deafness
Dizziness
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Fluid retention (an abnormal accumulation of fluid in the blood)
Glomerular filtration rate increased

What are the common drug interactions of Vitamin D and Tabrecta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Pneumonia

60+:

Fatigue (feeling of tiredness)
Decreased appetite
Deafness
Dysacusis (hearing impairment)
Ear discomfort
Hypoacusis (loss of hearing)
Throat irritation
Tinnitus (a ringing in the ears)
Breast cancer metastatic
Cardiac disorder

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 14 people, 37.84%
Lung Cancer - Non-Small Cell (lung cancer): 8 people, 21.62%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 5 people, 13.51%
Back Pain: 5 people, 13.51%
Nausea And Vomiting: 3 people, 8.11%
Nausea (feeling of having an urge to vomit): 3 people, 8.11%
Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 5.41%
Bronchial Carcinoma (lung cancer): 2 people, 5.41%
Breast Cancer: 2 people, 5.41%

* Approximation only. Some reports may have incomplete information.

Do you take Vitamin d and Tabrecta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously